文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克患者循环内皮细胞转化为成纤维细胞并与复苏液体量相关且可预测生存

Circulating Endothelial Cells From Septic Shock Patients Convert to Fibroblasts Are Associated With the Resuscitation Fluid Dose and Are Biomarkers for Survival Prediction.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论脓毒性休克患者循环内皮细胞急性转化为成纤维细胞,内皮与纤维化蛋白表达变化与复苏液体量相关,并可预测生存。

本研究为前瞻性研究,纳入ICU收治的43例患者(脓毒性休克与非脓毒性休克)及22名健康志愿者,检测循环成熟内皮细胞和内皮祖细胞的内皮与纤维化蛋白表达。脓毒性休克患者内皮蛋白下调、成纤维细胞特异性标志物升高,提示内皮纤维化转化;该表达变化幅度在脓毒性休克非存活者中更高,且内皮蛋白表达下降与复苏液体量的相关性优于APACHE II和SOFA评分。ROC曲线分析显示内皮蛋白表达水平预测脓毒性休克生存结局优于APACHE II和SOFA评分。结论认为循环内皮细胞急性转化为成纤维细胞,其蛋白表达变化与复苏液体量相关,可作为脓毒症早期生存诊断的生物标志物。

要点

  • 脓毒性休克患者循环成熟内皮细胞和内皮祖细胞出现内皮蛋白下调、成纤维细胞特异性标志物升高,提示内皮纤维化转化。
  • 内皮与纤维化蛋白表达变化幅度在脓毒性休克非存活者中更高,非脓毒性休克患者中无此差异。
  • 脓毒性休克非存活者中,内皮蛋白表达下降与复苏液体量的相关性优于APACHE II和SOFA评分。
  • 内皮与纤维化蛋白表达的显著差异提示脓毒性休克非生存结局,非脓毒性休克患者中无此提示。
  • ROC曲线分析显示内皮蛋白表达水平预测脓毒性休克生存结局优于APACHE II和SOFA评分。

适用人群与场景

  • ICU收治的脓毒性休克与非脓毒性休克患者,以及健康志愿者。

研究设计与关键结果

  • 前瞻性研究,纳入43例ICU患者和22名健康志愿者,比较脓毒性休克与非脓毒性休克患者循环内皮细胞的内皮与纤维化蛋白表达。
  • 脓毒性休克和非脓毒性休克患者的循环成熟内皮细胞和内皮祖细胞均显示内皮纤维化证据:内皮蛋白下调,成纤维细胞特异性标志物升高。
  • 内皮与纤维化蛋白表达变化幅度在脓毒性休克非存活者中更高,非脓毒性休克患者中无此差异。
  • 脓毒性休克非存活者中,内皮蛋白表达下降与复苏液体量的相关性优于APACHE II和SOFA评分;非脓毒性休克患者中无此相关性。
  • 内皮与纤维化蛋白表达的显著差异提示脓毒性休克非生存结局,非脓毒性休克患者中无此提示。
  • ROC曲线分析显示,内皮蛋白表达水平预测脓毒性休克生存结局优于APACHE II和SOFA评分;非脓毒性休克患者中无此优势。

证据类型、等级与局限

  • 证据类型:前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为循环内皮细胞的内皮与纤维化蛋白表达水平可作为脓毒症早期生存诊断的生物标志物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether circulating endothelial cells from septic shock patients and from nonseptic shock patients are transformed in activated fibroblast by changing the expression level of endothelial and fibrotic proteins, whether the level of the protein expression change is associated with the amount of administered resuscitation fluid, and whether this circulating endothelial cell protein expression change is a biomarker to predict sepsis survival.

DESIGN: Prospective study.

SETTING: Medical-surgical ICUs in a tertiary care hospital.

PATIENTS: Forty-three patients admitted in ICU and 22 healthy volunteers.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Circulating mature endothelial cells and circulating endothelial progenitor cells from septic shock and nonseptic shock patients showed evidence of endothelial fibrosis by changing the endothelial protein expression pattern. The endothelial proteins were downregulated, whereas fibroblast-specific markers were increased. The magnitude of the expression change in endothelial and fibrotic proteins was higher in the septic shock nonsurvivors patients but not in nonseptic shock. Interestingly, the decrease in the endothelial protein expression was correlated with the administered resuscitation fluid better than the Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores in the septic shock nonsurvivors patients but not in nonseptic shock. Notably, the significant difference between endothelial and fibrotic protein expression indicated a nonsurvival outcome in septic shock but not in nonseptic shock patients. Remarkably, area under the receiver operating characteristic curve analysis showed that endothelial protein expression levels predicted the survival outcome better than the Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores in septic shock but not in nonseptic shock patients.

CONCLUSIONS: Circulating endothelial cells from septic shock patients are acutely converted into fibroblasts. Endothelial and fibrotic protein expression level are associated with resuscitation fluid administration magnitude and can be used as biomarkers for an early survival diagnosis of sepsis.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Tapia P, Gatica S, Cortés-Rivera C, et al. Circulating Endothelial Cells From Septic Shock Patients Convert to Fibroblasts Are Associated With the Resuscitation Fluid Dose and Are Biomarkers for Survival Prediction. Crit Care Med. 2019. PMID: 30998606. doi:10.1097/CCM.0000000000003778

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。